Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6
Although WHO has declared an end to the emergency phase of the COVID-19 pandemic, SARS-CoV-2 has continued to spread and evolve, giving rise to new variants.
Guidance for Developing a Sustainable Multistakeholder Immunization Coalition
Insights from immunization coalition experts and analysis of successful immunization coalitions
International Pediatric COVID-19 Severity Over the Course of the Pandemic
This cohort study suggested that while intensive care unit admission decreased over the course of the pandemic in all age groups, ventilatory and oxygen support did not decrease over time in children aged younger than 5 years.
Pandemic preparedness, response and recovery: Lessons learnt for global pharmacy
Investing in science and innovation is one of six key areas of development needed to prepare for future pandemics, according to a new report conducted by the International Pharmaceutical Federation (FIP).
CYP19A1 mediates severe SARS-CoV-2 disease outcome in males
Male sex represents one of the major risk factors for severe COVID-19 outcome. However, underlying mechanisms that mediate sex-dependent disease outcome are as yet unknown.
COVID-19 pandemic: a catalyst for accelerating global action on patient safety
The disruption of health systems during the pandemic led to an increase in clinical risks and patient harm due to the accentuation of safety gaps, interruption of essential health services, and failure to provide timely diagnosis and treatment.
Co-evolution of immunity and seasonal influenza viruses
Seasonal influenza viruses cause recurring global epidemics by continually evolving to escape host immunity. The viral constraints and host immune responses that limit and drive the evolution of these viruses are increasingly well understood.
The SARS-CoV-2 Spike Protein Mutation Explorer: using an interactive application to improve the public understanding of SARS-CoV-2 variants of concern
The rapid evolution of SARS-CoV-2 resulted in variations in the spike that enhanced transmissibility or weakened vaccine protection.
TMEM106B is a receptor mediating ACE2-independent SARS-CoV-2 cell entry
SARS-CoV-2 is associated with broad tissue tropism, a characteristic often determined by the availability of entry receptors on host cells.
Dispersal patterns and influence of air travel during the global expansion of SARS-CoV-2 variants of concern
Long Covid: clues about causes
This investigated the monocyte and inflammatory profiles of individuals who were hospitalised with COVID-19 during the acute phase and the convalescent period.
SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination
This study demonstrates durable yet compartmentalised nasal IgA and plasma antibody responses to SARSCoV-2 after infection and subsequent vaccination.